| Trial ID: | L6633 |
| Source ID: | NCT05666128
|
| Associated Drug: |
Hd-6277
|
| Title: |
Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: HD-6277|DRUG: HD-6277|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in HbA1c(%) at weeks 12 from baseline, at weeks 12 from baseline |
|
| Sponsor/Collaborators: |
Sponsor: Hyundai Pharm
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
112
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-06-17
|
| Completion Date: |
2023-07-28
|
| Results First Posted: |
|
| Last Update Posted: |
2024-10-18
|
| Locations: |
Included Severance Hospital, 10 sites, Seoul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT05666128
|
